Last updated on November 2017

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma


Brief description of study

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma

Detailed Study Description

You are being asked to take part in this study because you are experiencing fatigue that is related to your cancer. Cancer related fatigue is a very common symptom in people with cancer.

The purpose of this study is to:
  • See if taking the study agent, armodafinil, at a dose of 150mg or 250mg, will improve problems with fatigue in patients who have been diagnosed with cancer and are experiencing fatigue.
  • See the effects (good and bad) of taking Armodafinil compared to placebo (an inactive agent) on cancer related fatigue.

Clinical Study Identifier: TX8079

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Pamela Treas

Baptist Health Clinical Research Center & Lexington Cardiac Research Foundation
Lexington, KY USA
  Connect »